Pharmaceutical and healthcare company Hutchison China MediTech, which counts Mitsui as an investor, priced its American depositary shares at $13.50 each.
Hutchison China MediTech (Chi-Med), a China-based healthcare group backed by conglomerate Mitsui, raised $101.3m when it floated on Nasdaq yesterday.
The company sold 7.5 million American depositary shares, each representing half a normal Chi-Med share, priced at $13.50 each. The underwriters have a 30-day option to buy another 1.125 million shares, which would lift the size of the initial public offering to $116.4m.
Chi-Med develops and produces pharmaceuticals and healthcare consumer products, and is focusing on the development of treatments…
